Breaking News - Candlesense

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-gener...

What potential regulatory pathway (e.g., FDA accelerated approval, cardiovascular outcome trial) does Marea anticipate for MAR001 if Phase 2b data are positive? How might the results of TYDAL‑TIMI 78 position MAR001 for advancement into a Phase 3 program, and what timelines are expected for that transition? What safety signals have emerged in Phase 1 or early Phase 2 data, and how might they influence investor sentiment?

Symbol: MREA

Clinical trials

21 days ago

Read more businesswire

Coca-Cola Beverages Florida Promotes Sales Veteran to Territory General Manager

TAMPA, Fla.--(BUSINESS WIRE)--Coca-Cola Beverages Florida, LLC (Coke Florida) announced the promotion of John C. Dearstine to Territory General Manager for the Fort Myers territory. “John’s deep in...

What potential risks or challenges could arise from the transition in leadership for the Fort Myers territory? How might this appointment influence investor sentiment and the stock price in the short‑term? Will the new Territory General Manager implement new pricing or promotional strategies that could affect margins?

Symbol: KO

Personnel

21 days ago

Read more businesswire

Macy’s Unveils First-Ever On 34th Collaboration

NEW YORK--(BUSINESS WIRE)--Macy’s announces its first-ever On 34th brand collaboration, in partnership with acclaimed costume designer Alix Friedberg and inspired by her work on the spirited world ...

How could the success or failure of this collaboration influence future designer partnerships for Macy’s? What are the inventory risk and supply‑chain considerations tied to this limited‑edition launch? Can the sales performance of the Palm Royale‑inspired collection be quantified on a per‑sku basis?

Symbol: M

Retail

21 days ago

Read more businesswire

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogen...

What are the company’s projected costs for advancing the DOSED trial through Phase 2/3, and how will this affect runway and potential dilution? Are there any disclosed adverse events or safety signals from this first patient that could raise concerns among investors? What is the estimated market size for subacute and chronic spinal cord injury treatments, and what share can Lineage realistically capture if trials are successful?

Symbol: LCTX

Clinical trials

21 days ago

Read more businesswire

TruBridge Re-Establishes Partnership With Jackson Parish Hospital to Boost Financial Performance and Outcomes

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ: TBRG), a leading healthcare solutions company, welcomes back Jackson Parish Hospital, a 25-bed critical access facility located in Jonesboro,...

Could this partnership trigger additional contract wins with other small‑to‑mid‑size hospitals in the region, creating a compounding growth effect? What potential risks does TruBridge face in expanding its CBO solution within the critical‑access market segment? Are there any upside or downside catalysts tied to the success of the Jackson Parish Hospital implementation that could move the stock?

Symbol: TBRG

Partnership

21 days ago

Read more businesswire

Verint Celebrates Customer AI Adoption Milestone and Rings Nasdaq Opening Bell

MELVILLE, N.Y.--(BUSINESS WIRE)-- #AI--Verint® (NASDAQ: VRNT), The CX Automation Company™, today celebrated its AI leadership in delivering meaningful, tangible AI business outcomes to customers by...

What risks could dampen the expected AI-driven revenue growth (e.g., churn, pricing pressure, competition)? How does Verint’s AI ARR growth affect its valuation multiples (e.g., EV/ARR) relative to peers? Is there any disclosed guidance on future AI ARR targets and their contribution to total ARR?

Symbol: VRNT

Earnings

21 days ago

Read more businesswire

Lincoln Electric Acquires Remaining Interest in Alloy Steel

CLEVELAND--(BUSINESS WIRE)-- #LEA--Lincoln Electric Holdings, Inc. (Nasdaq: LECO) (the “Company”) announced today that it has acquired the remaining 65% interest in Alloy Steel Australia (Int) Pty ...

Does the acquisition introduce any regulatory or compliance considerations that could affect Lincoln Electric’s operations in Australia or other markets? How did the market initially react to the announcement, and what is the expected price movement once the deal is reflected in the financial statements? What are the integration risks associated with fully absorbing Alloy Steel’s operations, and how is the company planning to mitigate them?

Symbol: LECO

Mergers

21 days ago

Read more businesswire

Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quar...

What is the implied valuation impact of this earnings release on the stock’s price‑to‑sales, price‑to‑earnings, and other valuation multiples? Are there any risks or uncertainties highlighted in the release (e.g., supply‑chain constraints, regulatory changes, or competitive pressures) that could impact the stock? How did the company's guidance and outlook affect analyst sentiment and target price revisions?

Symbol: TWST

Earnings

21 days ago

Read more businesswire

CommScope Reports Second Quarter 2025 Results

CLAREMONT, N.C.--(BUSINESS WIRE)-- #InvestorRelations--CommScope Holding Company, Inc. (NASDAQ: COMM), a global leader in network connectivity solutions, reported results for quarter ended June 30,...

How does CommScope’s performance position it against competitive pressure from legacy and emerging optical‑connectivity providers? Is there any impact from recent mergers, acquisitions, or divestitures on reported results? What macro‑economic factors (e.g., semiconductor shortage, supply‑chain disruptions) are highlighted as risks?

Symbol: COMM

Earnings

21 days ago

Read more businesswire

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ther...

How does Precision BioSciences’ valuation metrics (e.g., EV/Revenue, P/E, price/cash‑burn) compare to peer companies in the gene‑editing space? What are the potential short‑term catalysts (e.g., data releases, FDA meetings) that could move the stock after the August 7 announcement? Are there any material changes to the capital structure (e.g., stock issuances, debt financings, share buy‑backs) disclosed in the update?

Symbol: DTIL

Earnings

21 days ago

Read more businesswire